Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMONARCh-1: MSDC-0602K in T2D and NAFLD/NASH
NCT03970031Phase 3Unknown
- Sponsor
- Cirius Therapeutics
- Start
- Jun 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) comparing MSDC-0602K with Placebo (2 arms). Primary endpoints: Change in glycosylated hemoglobin (HbA1c) at 26 weeks and Change in the weighted average of standardized AST, CK-18, and HbA1c values at 26 weeks. Status: unknown.
02
Drugs
azemiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03970031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970031.